Matthews GV - Search Results

1

SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.

Tea F, Ospina Stella A, Aggarwal A, Ross Darley D, Pilli D, Vitale D, Merheb V, Lee FXZ, Cunningham P, Walker GJ, Fichter C, Brown DA, Rawlinson WD, Isaacs SR, Mathivanan V, Hoffmann M, Pöhlman S, Mazigi O, Christ D, Dwyer DE, Rockett RJ, Sintchenko V, Hoad VC, Irving DO, Dore GJ, Gosbell IB, Kelleher AD, Matthews GV, Brilot F, Turville SG. Tea F, et al. Among authors: matthews gv. PLoS Med. 2021 Jul 6;18(7):e1003656. doi: 10.1371/journal.pmed.1003656. eCollection 2021 Jul. PLoS Med. 2021. PMID: 34228725 Free PMC article.

2

Response to Soriano et al., 'Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis?'.

Matthews G, Dore G. Matthews G, et al. AIDS. 2003 Dec 5;17(18):2675-6. doi: 10.1097/01.aids.0000104338.15729.9a. AIDS. 2003. PMID: 14685063 No abstract available.

3

Treatment for hepatitis C virus infection among current injection drug users in Australia.

Matthews G, Kronborg IJ, Dore GJ. Matthews G, et al. Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S325-9. doi: 10.1086/427448. Clin Infect Dis. 2005. PMID: 15768342 Review.

4

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. Matthews GV, et al. AIDS. 2006 Apr 4;20(6):863-70. doi: 10.1097/01.aids.0000218550.85081.59. AIDS. 2006. PMID: 16549970

5

Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.

Matthews GV, Dore GJ. Matthews GV, et al. AIDS. 2007 Mar 30;21(6):777-8. doi: 10.1097/QAD.0b013e3280b07774. AIDS. 2007. PMID: 17413705 No abstract available.

6

Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.

Matthews GV, Cooper DA, Dore GJ. Matthews GV, et al. Antivir Ther. 2007;12(1):119-22. Antivir Ther. 2007. PMID: 17503756

7

The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure.

Matthews GV, Grebely J, Dore GJ. Matthews GV, et al. J Hepatol. 2008 Sep;49(3):305-7. doi: 10.1016/j.jhep.2008.06.005. Epub 2008 Jun 26. J Hepatol. 2008. PMID: 18644647 Free article. No abstract available.

8

HIV and hepatitis C coinfection.

Matthews GV, Dore GJ. Matthews GV, et al. J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1000-8. doi: 10.1111/j.1440-1746.2008.05489.x. J Gastroenterol Hepatol. 2008. PMID: 18707597 Review.

9

Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.

Lewin SR, Ribeiro RM, Avihingsanon A, Bowden S, Matthews G, Marks P, Locarnini SA, Ruxrungtham K, Perelson AS, Dore GJ. Lewin SR, et al. Hepatology. 2009 Apr;49(4):1113-21. doi: 10.1002/hep.22754. Hepatology. 2009. PMID: 19115219 Free PMC article. Clinical Trial.

10

Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy.

Crane M, Oliver B, Matthews G, Avihingsanon A, Ubolyam S, Markovska V, Chang JJ, Dore GJ, Price P, Visvanathan K, French M, Ruxrungtham K, Lewin SR. Crane M, et al. J Infect Dis. 2009 Apr 1;199(7):974-81. doi: 10.1086/597276. J Infect Dis. 2009. PMID: 19231993 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

248 results

Search Page